pharmaceuticals

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement…

2 months ago
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement…

2 months ago
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 10, 2025 17:15 ET  | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,…

2 months ago
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 10, 2025 17:15 ET  | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,…

2 months ago
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 02, 2025 16:53 ET  | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc.…

2 months ago
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years OldRhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years Old

BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

3 months ago
ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National FormulariesARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing…

3 months ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2024 16:05 ET | Source: X4 Pharmaceuticals BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR),…

3 months ago
Catalyst Pharmaceuticals Recognized as One of North Americas Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500 ListCatalyst Pharmaceuticals Recognized as One of North Americas Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500 List

Catalyst Pharmaceuticals Recognized as One of North Americas Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500 List

CORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today announced it ranked number…

4 months ago
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross ProceedsCyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

November 13, 2024 12:22 ET | Source: Cyclacel BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.…

4 months ago
Show more Posts
Show previous Posts